Published in Cancer Weekly, May 15th, 2006
"SLNM for staging in CRCa remains controversial and needs to be validated. This study analyzes results of SLNM at a multi-institutional level for CRCa. Group A patients underwent SLNM with 1 to 3 mL of 1% lymphazurin," researchers in the United States reported.
"First 1 to 4 blue lymph nodes were designated as SLNs and had focused analysis. Group B had standard resection and nodal staging. Patients with a minimum of 2 years of follow-up were analyzed for recurrence. Overall nodal metastasis were 50% for 500 group A patients versus 35% for 368 group B patients....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.